Bringing the fundamentals into focus…
Back to Tarsus Pharmaceuticals, Inc.
How Tarsus Pharmaceuticals, Inc. stacks up
TARS · against 302 other Healthcare companies of similar size
Profitability
28/ 100
Near the bottom of its peers.
Ranked #231 of 303 · scores higher than 23% of peers
Bars: peers in each 10-point band of the profitability score29 peers with a profitability score of 20–29, including TARS · Click a bar to see the companies
Why profitability scores 28?
Weighted metrics compared with all Healthcare companies.Mainly because of its return on invested capital, operating margin and return on assets, which are weaker than most Healthcare peers.
- a lower return on invested capital: weaker than 78% of peers. Return on invested capital: -17.8% vs peer median 4.7%
- a thinner operating margin: weaker than 74% of peers. Operating margin: -8.0% vs peer median 7.1%
- a lower return on assets: weaker than 73% of peers. Return on assets: -7.5% vs peer median 1.7%
Metric by metric
Position: dot = TARS, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | TARS | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Return on invested capitalHigher is better · 294 reported | -17.8% | 7.5% | 20% | 33% | |
| Operating marginHigher is better · 279 reported | -8.0% | 9.8% | 19% | 33% | |
| Return on assetsHigher is better · 286 reported | -7.5% | 2.7% | 24% | 33% | |
| Return on equityHigher is better · 281 reported | -13.7% | 6.9% | 28% | Context only | |
| Gross marginHigher is better · 310 reported | 82.7% | 47.6% | 92% | Context only |
Ranking by profitability score
Top 5 and the companies ranked around TARS| Rank | Company | Market cap | Profitability | Overall |
|---|---|---|---|---|
| 1 | 3.1B EUR (≈$3.4B) | 100 | 100 | |
| 1 | 321.5B INR (≈$3.9B) | 100 | 70 | |
| 1 | 174.8B INR (≈$2.1B) | 100 | 73 | |
| 4 | 12.3B CNY (≈$1.7B) | 99 | 85 | |
| 4 | 51.3B ZAR (≈$2.8B) | 99 | 73 | |
| 228 | 2.9B USD | 29 | 44 | |
| 228 | 1.8B USD | 29 | 31 | |
| 231 | 15.4B HKD (≈$2.0B) | 28 | 44 | |
| 231 | 6.0B USD | 28 | 30 | |
| 231 | 3.4B USD | 28 | 48 | |
| 234 | 6.1B USD | 26 | ||
| 234 | 3.3B USD | 26 | 44 | |
| 234 | 6.6B USD | 26 | 45 | |
| 237 | 4.1B USD | 25 | 39 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score